Literature DB >> 22378923

Toward a meningitis-free world.

Steven Black1, Mariagrazia Pizza, Mikkel Nissum, Rino Rappuoli.   

Abstract

Meningococcal meningitis is a devastating disease that is often fatal. Vaccines against the five major meningococcal serogroups causing disease are about to become available, a conjugate vaccine against meningococcus A is in use for mass vaccination in Africa, and a protein-based vaccine against meningococcal B is ready for licensure. With the availability of these new vaccines, the world can finally be rid of meningococcal meningitis, thus rewriting a new chapter in medical history.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22378923     DOI: 10.1126/scitranslmed.3003859

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  9 in total

1.  Structure of the meningococcal vaccine antigen NadA and epitope mapping of a bactericidal antibody.

Authors:  Enrico Malito; Marco Biancucci; Agnese Faleri; Ilaria Ferlenghi; Maria Scarselli; Giulietta Maruggi; Paola Lo Surdo; Daniele Veggi; Alessia Liguori; Laura Santini; Isabella Bertoldi; Roberto Petracca; Sara Marchi; Giacomo Romagnoli; Elena Cartocci; Irene Vercellino; Silvana Savino; Glen Spraggon; Nathalie Norais; Mariagrazia Pizza; Rino Rappuoli; Vega Masignani; Matthew James Bottomley
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-17       Impact factor: 11.205

Review 2.  Bexsero® chronicle.

Authors:  George Vernikos; Duccio Medini
Journal:  Pathog Glob Health       Date:  2014-10       Impact factor: 2.894

Review 3.  Meningococcal B vaccine and the vision of a meningitis free world.

Authors:  A Bianchi; S Fantoni; A Prugnola
Journal:  J Prev Med Hyg       Date:  2015-08-31

Review 4.  Changing Priorities in Vaccinology: Antibiotic Resistance Moving to the Top.

Authors:  Aldo Tagliabue; Rino Rappuoli
Journal:  Front Immunol       Date:  2018-05-30       Impact factor: 7.561

5.  NadA3 Structures Reveal Undecad Coiled Coils and LOX1 Binding Regions Competed by Meningococcus B Vaccine-Elicited Human Antibodies.

Authors:  Alessia Liguori; Lucia Dello Iacono; Giulietta Maruggi; Barbara Benucci; Marcello Merola; Paola Lo Surdo; Jacinto López-Sagaseta; Mariagrazia Pizza; Enrico Malito; Matthew J Bottomley
Journal:  mBio       Date:  2018-10-16       Impact factor: 7.867

Review 6.  The Impact of Nucleotide Sequence Analysis on Meningococcal Vaccine Development and Assessment.

Authors:  Martin Christopher James Maiden
Journal:  Front Immunol       Date:  2019-01-15       Impact factor: 7.561

7.  A re-assessment of 4CMenB vaccine effectiveness against serogroup B invasive meningococcal disease in England based on an incidence model.

Authors:  Lorenzo Argante; Victoria Abbing-Karahagopian; Kumaran Vadivelu; Rino Rappuoli; Duccio Medini
Journal:  BMC Infect Dis       Date:  2021-12-11       Impact factor: 3.090

8.  Design and evaluation of meningococcal vaccines through structure-based modification of host and pathogen molecules.

Authors:  Steven Johnson; Lionel Tan; Stijn van der Veen; Joseph Caesar; Elena Goicoechea De Jorge; Rachel J Harding; Xilian Bai; Rachel M Exley; Philip N Ward; Nicola Ruivo; Kaushali Trivedi; Elspeth Cumber; Rhian Jones; Luke Newham; David Staunton; Rafael Ufret-Vincenty; Ray Borrow; Matthew C Pickering; Susan M Lea; Christoph M Tang
Journal:  PLoS Pathog       Date:  2012-10-25       Impact factor: 6.823

9.  Fast and accurate dynamic estimation of field effectiveness of meningococcal vaccines.

Authors:  Lorenzo Argante; Michele Tizzoni; Duccio Medini
Journal:  BMC Med       Date:  2016-06-30       Impact factor: 8.775

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.